Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03004 following
an escalating single intramuscular injection at 12.5, 25, 37.5, or 50 mg; and to evaluate the
safety and tolerability and preliminary efficacy of LY03004 following intramuscular
injection.